The World Intellectual Property Organization (WIPO) will host a “Conference on Open Innovation: Collaborative Projects and the Future of Knowledge” on 22-23 January 2014 at its headquarters in Geneva, Switzerland.
The origins of this conference on open collaborative development models is predicated upon Recommendation 36 of the WIPO Development Agenda which states:
Continue Reading →
Today Senators Bacus and Hatch introduced fast track legislation in the Senate. The words transparent or transparency appear 17 times in the 107 page bill, but only twice in connection with “Trade Institution Transparency.”
Continue Reading →
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading →
From Amgen’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Item 1A. RISK FACTORS
Continue Reading →
From Gilead’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in section 1A: 12709
Words on compulsory licenses: 396
ITEM 1A. RISK FACTORS
Continue Reading →
From Johnson & Johnson’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 1314
Compulsory licensing of patents: 0
Item 1A.RISK FACTORS
Continue Reading →
From Roche’s Risk Management and Compliance site, section on Risk Factors, dated May 2012.
Number of words in Risk Factor document: 360
Compulsory licensing of patents: 0
Risk factors
Principal risks and uncertainties
Continue Reading →
From Sanofi’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10577
Compulsory licensing of patents: 43
3D. Risk Factors
Continue Reading →
From Novartis’ 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10297
Compulsory licensing of patents: 55
Earthquake risk: 96
3.D Risk Factors
Continue Reading →
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading →